Opendata, web and dolomites

ProCenDecl SIGNED

Synthesis and validation of chemical Probes for Centrosome Declustering: development of potent and selective anti-cancer agents.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ProCenDecl project word cloud

Explore the words cloud of the ProCenDecl project. It provides you a very rough idea of what is the project "ProCenDecl" about.

provides    specificity    led    completely    proteomics    enzyme    catastrophe    centrosomes    anti    pseudo    sar    parps    compound    action    photoaffinity    uneven    astrazeneca    orally    starting    survival    az9482    seems    division    tankyrase    exploited    normal    cancer    spindle    tnks1    potently    cell    accumulate    library    polimerase    ligation    form    first    inhibitors    tools    centrosome    extensive    consequent    drugs    tumor    prevention    polymerase    family    copies    declustering    mitotic    potent    synthesize    multipolar    druggability    clustering    organization    series    selective    chemical    16    organelles    advantage    ribose    adp    technologies    employed    contrary    leads    phtalazinone    responsible    aberrant    point    microtubules    reports    spindles    bipolar    conjugation    chromosomes    derivative    az0108    daughter    discovery    ribosylation    inhibitor    mode    investigation    cells    biorthogonal    extra    acquired    inhibit    tendency    parp    poly    segregation    mechanism   

Project "ProCenDecl" data sheet

The following table provides information about the project.

Coordinator
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE 

Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD
city: LONDON
postcode: SW7 2AZ
website: http://www.imperial.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) coordinator 183˙454.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Cancer cells have the tendency to accumulate extra copies of centrosomes, organelles responsible for the microtubules' organization during cell division. In normal cells, an aberrant number of centrosomes leads to the formation of multipolar spindles, uneven segregation of chromosomes between daughter cells and consequent mitotic catastrophe. On the contrary, cancer cells are able to form a pseudo-bipolar mitotic spindle by a process called centrosome clustering, which provides survival advantage for tumor cells. The specificity of this process can be exploited as a potential novel target for the development of highly selective anti-cancer drugs. The mechanism of centrosome clustering is not completely understood. Particularly, from recent reports it seems that ADP ribosylation factors tankyrase (TNKS1) and ADP-ribose polimerase 16 (PARP-16) have a significant role in the prevention of multipolar spindle formation. Based on these findings and the already druggability of poly (ADP-ribose) polymerase (PARP) enzyme family, a SAR study on phtalazinone PARP inhibitors from AstraZeneca's compound library was carried out. This study led to the discovery of AZ9482, a potent inhibitor of centrosome clustering, and AZ0108 an orally available derivative that is able to potently inhibit PARPs 1/2/6. AZ9482 as well as AZ0108 can be used as a starting point to design and synthesize a first series of chemical proteomics tools, that will allow an extensive investigation of the centrosome declustering mechanism. All currently available technologies in the field of target discovery will be employed, including photoaffinity ligation and biorthogonal conjugation. The acquired knowledge can be used to design novel highly specific and potent anti-cancer drugs that inhibit centrosome clustering with a specific mode of action.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROCENDECL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROCENDECL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

TCFLAND2SEA (2020)

Thawing Carbon From LAND to SEA: Microbial Degradation of Organic Matter and Response to Thawing Permafrost in the Northeast Siberian Land-Shelf System

Read More